Market Update (NYSE:PFE): Pfizer Announces FDA Acceptance Of And Priority Review Designation For Biologics License Application For Investigational Meningococcal B Vaccine

[Business Wire] – Pfizer Inc. announced today that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for bivalent recombinant LP2086 , the company’s vaccine candidate for the . . . → Read More: Market Update (NYSE:PFE): Pfizer Announces FDA Acceptance Of And Priority Review Designation For Biologics License Application For Investigational Meningococcal B Vaccine Similar Articles: Stock Update (NYSE:PFE): Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy Lyrica® Studies Conducted in China Market Update (NYSE:PFE): Pfizer Enters Into Agreement to Acquire Baxter’s Portfolio of Marketed Vaccines Merck & Co. Inc. (NYSE:MRK) – 8:31 am Merck initiates rolling submission of U.S. Biologics License Application for MK-3475, an investigational Anti-PD-1 Immunotherapy, in patients with advanced melanoma; expects to complete application in 1H14